Quick Heal Technologies Ltd

- There is no mention of any current or future fundraising through debt or equity in the provided pages. - The company plans to use approximately ₹200 crore available in its books (post buyback and dividend) for organic and inorganic growth opportunities. - Investments are mainly focused on R&D and product development rather than raising external capital. - The management emphasizes internal funding for growth, with ₹150 crore already invested in R&D over the last two years. - No plans for external equity or debt fundraising were discussed during the Q&A or management commentary.

- The company’s major investment focus is on R&D rather than traditional Capex, which is described as very limited or insignificant in the larger scheme of things. - Recent R&D investments (close to ₹150 crores in last two years) target improving existing products and developing new ones, especially in zero trust, data privacy, endpoint security, and enterprise products. - Strategic investment includes a sizable stake in an Israeli entity specializing in future technology (endpoint security), which is progressing well in product development. - The company plans to use approximately ₹200 crore available after buyback and dividend for organic and inorganic growth opportunities. - They have also onboarded a top global consultancy to help shape long-term strategic growth. - No major standalone Capex plans were mentioned, with emphasis placed on investment in product development and marketing to capture market growth.

- Enterprise business is growing rapidly (50% YoY growth in Q1 FY23) and currently forms about one-third of total revenue, with a target to reach a 50-50 mix with retail in the next two years. - Retail (consumer) segment is relatively flat, with growth in India at about 1%, but the company maintains the highest market share (~30%). - New products in Zero Trust, Data Privacy, EDR, and XDR are in beta/pilot stages; revenue from these is expected to start flowing from H1 FY24 onward. - Future revenue growth will be driven by enterprise sales, with ongoing investment in R&D and marketing. - Management’s vision targets reasonable revenue growth, focusing on building product-market fit for emerging technologies and expanding enterprise clientele, including larger organizations. - Awareness and demand generation, especially in enterprise, will influence future volume and sales growth. - Overall, expect modest retail growth, strong enterprise growth, and gradual revenue ramp-up from new cybersecurity products over the next 3-5 years.

- The company aims for a balanced revenue mix of 50-50 between retail and enterprise segments in the next two years, with enterprise expected to grow faster (around 11% globally). - Current revenue growth is modest, with retail segment flat at about 1% growth in India, but enterprise business grew ~50% YoY in Q1 FY23. - Significant investment in R&D (around ₹150 crore over two years) targets future products like Zero Trust and Data Privacy, expected to generate revenues starting H1 FY24. - New product launches (e.g., Zero Trust User Access) have started onboarding customers, with revenue traction expected over 4-6 quarters. - Operating profits are impacted by increased R&D and sales & marketing expenses as part of growth investments. - The management expects reasonable revenue growth with continued cost optimization aiming for better profitability over the medium term. - EPS improvement has been supported by buybacks; organic growth in earnings is expected to pick up with new products gaining market acceptance.

- The transcript does not explicitly mention the current or expected order book or pending orders for Quick Heal Technologies Limited. - Management emphasizes focus on product launches, particularly in enterprise security, with growing demand for new products like Zero Trust and Data Privacy solutions. - They highlighted increasing traction and onboarding early customers for these new products, suggesting a growing pipeline. - No specific quantitative details regarding order book size or pending orders were disclosed. - Emphasis is on building product-market fit over 4 to 6 quarters, with revenues expected from H1 FY24. - Growth in enterprise segment revenue by around 50% YoY in Q1 FY23 indicates a robust order pipeline but no direct order book figures provided. - Overall, no concrete data on pending or confirmed orders is shared in the transcript.